Stifel keeps Buy rating on Hinge Health with $130 price target
Stifel analysts reiterated a Buy rating on Hinge Health with a $130 price target, implying 16.6% upside from the October 23 close of $111.52.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, citing Benzinga data, Stifel has kept its Buy rating on Hinge Health shares and set a price target of $130. The target implies a 16.6% gain from the October 23 close of $111.52.
The Stifel note expects Hinge Health's organic revenue to grow 44% year over year in the third quarter of 2026, and past trends suggest the actual figure could be nearer 50%. The firm also forecasts 33% revenue growth for 2027. September downloads hit the highest monthly total of 2026, up 100% year over year, while retention and engagement metrics improved.
why it matters
For markets, this points to strong fundamentals: accelerating revenue and rising user activity matter when valuing the stock. A single brokerage note carries limited weight, but such revisions can shape sentiment around digital health shares.
tags
instruments
sources
- Stifel maintains Buy rating on Hinge Health, $130 price target — TradingView, 26 October 2026 at 16:19 UTC
- Stifel maintains Buy rating on ORIC Pharmaceuticals, $18 price target — TradingView, 26 October 2026 at 16:44 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗